BridgeBio Oncology Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
84
- Stock Symbol
-
BBOT
- Investments
-
1
- Share Price
-
$1.98
- (As of Monday Closing)
BridgeBio Oncology Therapeutics General Information
Description
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
Contact Information
Website
www.bbotx.comCorporate Office
- 256 East, Grand Avenue
- Suite 104
- South San Francisco, CA 94080
- United States
Corporate Office
- 256 East, Grand Avenue
- Suite 104
- South San Francisco, CA 94080
- United States
BridgeBio Oncology Therapeutics Timeline
BridgeBio Oncology Therapeutics Stock Performance
As of 16-Nov-2026, BridgeBio Oncology Therapeutics’s stock price is $1.98. Its current market cap is $158M with 80.3M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.98 | $2.13 | $1.97 - $14.87 | $158M | 80.3M | 623K | -$2.15 |
BridgeBio Oncology Therapeutics Financials Summary
As of 30-Sep-2026, BridgeBio Oncology Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 105,517 | 536,060 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (185,951) | (144,777) | (80,444) | (64,679) |
| Net Income | (171,533) | (134,044) | (74,275) | (64,699) |
| Total Assets | 346,224 | 448,381 | 164,301 | 5,942 |
| Total Debt | 2,381 | 2,766 | 0 | 0 |
BridgeBio Oncology Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BridgeBio Oncology Therapeutics Signals
BridgeBio Oncology Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
BridgeBio Oncology Therapeutics Acquisitions (1)
BridgeBio Oncology Therapeutics’s most recent deal was a Merger/Acquisition with Helix Acquisition II. The deal was made on 11-Aug-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Helix Acquisition II | 11-Aug-2025 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
BridgeBio Oncology Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
BridgeBio Oncology Therapeutics FAQs
-
When was BridgeBio Oncology Therapeutics founded?
BridgeBio Oncology Therapeutics was founded in 2016.
-
Where is BridgeBio Oncology Therapeutics headquartered?
BridgeBio Oncology Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of BridgeBio Oncology Therapeutics?
BridgeBio Oncology Therapeutics has 84 total employees.
-
What industry is BridgeBio Oncology Therapeutics in?
BridgeBio Oncology Therapeutics’s primary industry is Drug Discovery.
-
Is BridgeBio Oncology Therapeutics a private or public company?
BridgeBio Oncology Therapeutics is a Public company.
-
What is BridgeBio Oncology Therapeutics’s stock symbol?
The ticker symbol for BridgeBio Oncology Therapeutics is BBOT.
-
What is the current stock price of BridgeBio Oncology Therapeutics?
As of 16-Nov-2026 the stock price of BridgeBio Oncology Therapeutics is $1.98.
-
What is the current market cap of BridgeBio Oncology Therapeutics?
The current market capitalization of BridgeBio Oncology Therapeutics is $158M.
-
What is BridgeBio Oncology Therapeutics’s annual earnings per share (EPS)?
BridgeBio Oncology Therapeutics’s EPS for 12 months was -$2.15.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process